<\/p>\n
Brom<\/strong> je peror\u00e1ln\u00ed bromocriptine<\/strong> (2.5 mg) tablet \u2014 an ergot-derived dopamine agonist<\/strong> with a triple indication: Parkinson disease<\/strong> (especially as adjunct therapy when motor fluctuations develop on levodopa), hyperprolaktin\u00e9mii<\/strong> (high prolactin causing infertility, amenorrhoea, galactorrhoea or low testosterone), and acromegaly<\/strong> (excess growth hormone). It directly stimulates dopamine D2 receptors and (in the pituitary) suppresses prolactin secretion. D\u016fle\u017eit\u00e9:<\/strong> ergot agonists can cause cardiac valve fibrosis<\/em> a pleural\/pericardial\/retroperitoneal fibrosis<\/em> with chronic high-dose use — an issue not seen with non-ergot agonists (ropinirole, pramipexole, piribedil). Echocardiogram screening is recommended for long-term users.<\/p>\n<\/div>\n \ud83d\udce6 Ka\u017ed\u00e1 objedn\u00e1vka je pokryta na\u0161\u00ed Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/strong><\/a> \u2014 pokud va\u0161e z\u00e1silka nedoraz\u00ed do 20 pracovn\u00edch dn\u016f, p\u0159epos\u00edl\u00e1me ji.<\/p>\n Na\u0161e generick\u00e9 l\u00e9ky poch\u00e1zej\u00ed od v\u00fdrobc\u016f certifikovan\u00fdch WHO-GMP a jsou expedov\u00e1ny po cel\u00e9m sv\u011bt\u011b v diskr\u00e9tn\u00edm, nen\u00e1padn\u00e9m balen\u00ed \u2013 na vn\u011bj\u0161\u00ed stran\u011b bal\u00edku nen\u00ed uveden n\u00e1zev l\u00e9ku. Platby kartou jsou sm\u011brov\u00e1ny prost\u0159ednictv\u00edm regulovan\u00e9ho procesoru (popisky na v\u00fdpisu zahrnuj\u00ed regulovan\u00e9ho procesora plateb kartou \u2013 nikdy \u201cMedsBase\u201d nebo n\u00e1zev l\u00e9ku). P\u0159ij\u00edm\u00e1me tak\u00e9 kryptom\u011bny a bankovn\u00ed p\u0159evody SEPA. Ka\u017ed\u00e1 objedn\u00e1vka je zaji\u0161t\u011bna na\u0161\u00ed politikou p\u0159eposl\u00e1n\u00ed.<\/p>\n Brom is an oral tablet containing bromocriptine 2.5 mg<\/strong>. Bromocriptine is the original ergot-derived dopamine agonist, marketed since the 1970s as Parlodel<\/strong>. It has three classical indications:<\/p>\n Brom is manufactured by a WHO-GMP certified facility and is bioequivalent to the originator brand at 2.5 mg.<\/p>\n Bromocriptine is a direct D2 dopamine receptor agonist<\/strong> with weak D1 antagonism, derived from the ergot alkaloid family. Its actions:<\/p>\n Because bromocriptine is an ergot, it also binds 5-HT2B serotonin receptors<\/strong> on heart valves and connective tissue — the basis of the rare but serious fibrotic side effects.<\/p>\n Parkinson disease:<\/strong> historically a first-line dopamine agonist; most neurologists today start with a non-ergot agonist (ropinirole, pramipexole) because of the fibrosis risk. Brom remains useful when newer agonists are intolerable, unavailable, or cost-prohibitive, and as adjunct to levodopa in fluctuating patients.<\/p>\n Hyperprolactinaemia \/ prolactinoma:<\/strong> still widely used. Cabergoline is now usually preferred (twice-weekly dosing, fewer GI effects) but bromocriptine remains effective and is the standard option in pregnancy because it has the longest safety record.<\/p>\n Acromegaly:<\/strong> second-line, mostly for patients who cannot tolerate or afford somatostatin analogues (octreotide, lanreotide).<\/p>\n Lactation suppression after stillbirth or maternal contraindication to breastfeeding:<\/strong> historically used, but now rarely recommended<\/em> because of cases of stroke, hypertension and seizures — non-pharmacological measures and cabergoline are usually preferred.<\/p>\n Not appropriate for:<\/strong> uncontrolled hypertension, severe coronary or peripheral vascular disease, history of valvular heart disease, current ergot alkaloid use (ergotamine, methysergide).<\/p>\nPro\u010d objedn\u00e1vat z MedsBase<\/h3>\n
What Is Brom?<\/h2>\n
\n
How Does Brom (Bromocriptine) Work?<\/h2>\n
\n
Who Is Brom For?<\/h2>\n
Dosing and Titration<\/h2>\n